Phase II trial reports leukemia remissions using engineered T cell therapy

October 15, 2014 9:37 PM

16 0

1. 90% of relapsed B-cell acute lymphoblastic leukemia (ALL) patients achieved complete remission 1 month after an infusion of engineered T-cells.

2. All patients developed the cytokine-release syndrome requiring hospitalization.

Read more

To category page